<?xml version='1.0' encoding='utf-8'?>
<document id="21515813"><sentence text="In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban."><entity charOffset="65-76" id="DDI-PubMed.21515813.s1.e0" text="rivaroxaban" /></sentence><sentence text="Rivaroxaban, an oral, direct factor Xa inhibitor, has a dual mode of elimination in humans, with two-thirds metabolized by the liver and one-third renally excreted unchanged"><entity charOffset="0-11" id="DDI-PubMed.21515813.s2.e0" text="Rivaroxaban" /></sentence><sentence text=" P-glycoprotein (P-gp) is known to be involved in the absorption, distribution, and excretion of drugs" /><sentence text=" To investigate whether rivaroxaban is a substrate of P-gp, the bidirectional flux of rivaroxaban across Caco-2, wild-type, and P-gp-overexpressing LLC-PK1 cells was investigated"><entity charOffset="24-35" id="DDI-PubMed.21515813.s4.e0" text="rivaroxaban" /><entity charOffset="86-97" id="DDI-PubMed.21515813.s4.e1" text="rivaroxaban" /><pair ddi="false" e1="DDI-PubMed.21515813.s4.e0" e2="DDI-PubMed.21515813.s4.e0" /><pair ddi="false" e1="DDI-PubMed.21515813.s4.e0" e2="DDI-PubMed.21515813.s4.e1" /></sentence><sentence text=" Furthermore, the inhibitory effect of rivaroxaban toward P-gp was determined"><entity charOffset="39-50" id="DDI-PubMed.21515813.s5.e0" text="rivaroxaban" /></sentence><sentence text=" Rivaroxaban exhibited high permeability and polarized transport across Caco-2 cells"><entity charOffset="1-12" id="DDI-PubMed.21515813.s6.e0" text="Rivaroxaban" /></sentence><sentence text=" Rivaroxaban was shown to be a substrate for, but not an inhibitor of, P-gp"><entity charOffset="1-12" id="DDI-PubMed.21515813.s7.e0" text="Rivaroxaban" /></sentence><sentence text=" Of a set of potential P-gp inhibitors, ketoconazole and ritonavir, but not clarithromycin or erythromycin, inhibited P-gp-mediated transport of rivaroxaban, with half-maximal inhibitory concentration values in the range of therapeutic plasma concentrations"><entity charOffset="40-52" id="DDI-PubMed.21515813.s8.e0" text="ketoconazole" /><entity charOffset="57-66" id="DDI-PubMed.21515813.s8.e1" text="ritonavir" /><entity charOffset="76-90" id="DDI-PubMed.21515813.s8.e2" text="clarithromycin" /><entity charOffset="94-106" id="DDI-PubMed.21515813.s8.e3" text="erythromycin" /><entity charOffset="145-156" id="DDI-PubMed.21515813.s8.e4" text="rivaroxaban" /><pair ddi="false" e1="DDI-PubMed.21515813.s8.e0" e2="DDI-PubMed.21515813.s8.e0" /><pair ddi="false" e1="DDI-PubMed.21515813.s8.e0" e2="DDI-PubMed.21515813.s8.e1" /><pair ddi="false" e1="DDI-PubMed.21515813.s8.e0" e2="DDI-PubMed.21515813.s8.e2" /><pair ddi="false" e1="DDI-PubMed.21515813.s8.e0" e2="DDI-PubMed.21515813.s8.e3" /><pair ddi="false" e1="DDI-PubMed.21515813.s8.e0" e2="DDI-PubMed.21515813.s8.e4" /><pair ddi="false" e1="DDI-PubMed.21515813.s8.e1" e2="DDI-PubMed.21515813.s8.e1" /><pair ddi="false" e1="DDI-PubMed.21515813.s8.e1" e2="DDI-PubMed.21515813.s8.e2" /><pair ddi="false" e1="DDI-PubMed.21515813.s8.e1" e2="DDI-PubMed.21515813.s8.e3" /><pair ddi="false" e1="DDI-PubMed.21515813.s8.e1" e2="DDI-PubMed.21515813.s8.e4" /><pair ddi="false" e1="DDI-PubMed.21515813.s8.e2" e2="DDI-PubMed.21515813.s8.e2" /><pair ddi="false" e1="DDI-PubMed.21515813.s8.e2" e2="DDI-PubMed.21515813.s8.e3" /><pair ddi="false" e1="DDI-PubMed.21515813.s8.e2" e2="DDI-PubMed.21515813.s8.e4" /><pair ddi="false" e1="DDI-PubMed.21515813.s8.e3" e2="DDI-PubMed.21515813.s8.e3" /><pair ddi="false" e1="DDI-PubMed.21515813.s8.e3" e2="DDI-PubMed.21515813.s8.e4" /></sentence><sentence text=" These findings are in line with observed area under the plasma concentration-time curve increases in clinical drug-drug interaction studies indicating a possible involvement of P-gp in the distribution and excretion of rivaroxaban"><entity charOffset="220-231" id="DDI-PubMed.21515813.s9.e0" text="rivaroxaban" /></sentence><sentence text=" In vivo studies in wild-type and P-gp double-knockout mice demonstrated that the impact of P-gp alone on the pharmacokinetics of rivaroxaban is minor"><entity charOffset="130-141" id="DDI-PubMed.21515813.s10.e0" text="rivaroxaban" /></sentence><sentence text=" However, in P-gp double-knockout mice, a slight increase in brain concentrations and decreased excretion into the gastrointestinal tract were observed compared with wild-type mice" /><sentence text=" These studies also demonstrated that brain penetration of rivaroxaban is fairly low"><entity charOffset="59-70" id="DDI-PubMed.21515813.s12.e0" text="rivaroxaban" /></sentence><sentence text=" In addition to P-gp, a further transport protein might be involved in the secretion of rivaroxaban"><entity charOffset="88-99" id="DDI-PubMed.21515813.s13.e0" text="rivaroxaban" /></sentence><sentence text="" /></document>